Chiron Real Estate Bets on Senior Housing After 36% Dividend Cut

A medical office landlord rebuilds itself

For more than a decade, Global Medical REIT was a simple business to explain. It bought purpose-built healthcare facilities and leased them on net terms to physician groups and hospital systems. In 2026 the company set that model aside. On February 23 it renamed itself Chiron Real Estate Inc. and switched its New York Stock Exchange ticker from GMRE to XRN.5 Its Series A and Series B preferred shares moved to the new symbol too. The company said the change would not affect its REIT tax status or its organizational structure.13

The new name was the small part. Over the following months Chiron cut its dividend, sold a large block of legacy assets and raised convertible preferred capital from an activist-style investor. It also bought its first senior housing operating properties. Supporters call this a turnaround the market has not caught up with. As of October 9, the stock had not delivered on that view: shares closed at $33.59, giving the company a market value of roughly $445 million to $486 million depending on the data provider.1114

Why management walked away from steady outpatient income

The case for change starts with the limits of the old business. CEO Mark Decker, Jr. joined in June 2025. He had already led one repositioning as CEO of multifamily REIT Centerspace and spent almost 20 years in REIT banking before that.7 He calls outpatient medical a very consistent business, with net operating income growth that has stayed between 2% and 3% a year for about 25 years.7 He also concedes that this kind of growth does not always give investors the expansion they want.7

The new pitch is "essential health care" real estate: assets connected to an aging population and to changes in how care is delivered, where Decker thinks double-digit unlevered returns are possible.7 He has singled out modern active adult housing as an underbuilt niche, with fewer than 50,000 apartment homes in that category today.7 In January 2026 the company put $7.1 million into a 49% stake in a joint venture building a 132-unit luxury active adult community near Minneapolis. That project is backed by a $31.0 million construction loan.8

Decker has also said plainly that he thinks the stock is undervalued. He has pointed to about $250 million of assets in the market for sale or recapitalization. He has also said the company has not decided whether senior and active adult exposure should reach 20% or 70% of the portfolio.7 That open question explains much of how investors are pricing the shares.

The deals: senior housing in, rehab hospitals out

In May, Chiron agreed to buy three newly built senior housing communities from affiliates of Silverstone Senior Living for $425 million in total.17 Two are in Alexandria, Virginia, priced at about $249 million together, and one is in North Bethesda, Maryland, at about $176 million. All three offer some mix of independent living, assisted living and memory care.2

Some coverage describes the full $425 million purchase as done.15 The company's own second-quarter figures show only $249 million closed in the quarter, covering The Landing and The Riviera.27 Going by the filings, the pivot is partly complete. The North Bethesda deal is the next milestone to watch.

The sale side of the plan was just as important. On June 30, Chiron moved seven inpatient rehabilitation facilities, valued at about $217 million, into a joint venture with a U.S. public pension fund. It kept a 15% stake and continues to manage the assets.2 The sale priced at a 7.3% exit cash cap rate.27 It produced a $71.9 million gain, which turned the second quarter into $63.3 million of net income to common stockholders, or $4.78 per diluted share. A year earlier the company had posted a loss.23

Paying for it: the preferred deal, debt and the dividend

To pay for the move, Chiron sold $100 million of 6.00% Series C convertible perpetual preferred stock to an investor group led by Maewyn Capital Partners. The dividend rate rises after four years if the shares are still outstanding.21 They convert at $43.00 per common share.23 Maewyn founder Charles Fitzgerald joined the board in May. He holds 97,293 common shares through affiliated entities.24

The balance sheet improved. Leverage fell to 39.9% of total gross assets at June 30, from 44.7% at the end of March. About 78% of the debt carries fixed rates, and nothing matures in 2026 or 2027.23 Net debt to adjusted EBITDAre came down to 6.0x from 6.6x.27

Financing costs are a different matter. Interest rate swaps on $350 million of debt had fixed rates at 1.36%. When they matured, the replacements fixed the rate at 3.29%. At year-end 2025 the weighted average interest rate on the company's debt was 3.74%.8 Much of the company's cheap financing from earlier years is now gone. Repricing like this is hitting borrowers across commercial real estate.

Shareholders felt the cost most directly in the dividend. Chiron had moved to monthly payments in February and kept the annual rate at $3.00.8 A few months later it cut the monthly payout from $0.25 to $0.16, a reduction of about 36%, to keep cash for acquisitions.28 The forward yield is now about 5.7%.11

What the numbers say so far

The operating results still show the cost of the transition. Second-quarter funds from operations were $0.88 per share, down from $0.98. Core FFO fell to $1.04 from $1.14.21 Same-property cash NOI in the outpatient medical portfolio grew just 0.8% from a year earlier.21 Excluding a one-time item, that figure was 1.7%.28 Both are well below the 5.4% the company reported for the fourth quarter of 2025.7 Outpatient occupancy was 95%, and annualized cash NOI for that segment was $100 million.27 Resident fees from the new senior housing properties appeared for the first time, at $1.8 million.26

There is also some tenant risk. White Rock, the operator of a Chiron hospital in Dallas, filed for Chapter 11 in January 2026.8

Why analysts disagree so much

Analysts are split. Price targets run from $9 to $46, with an average of about $38.56.11 Over the year, one analyst cut a target from $33.05 to $14.32, citing expected earnings dilution from the senior housing shift. Others raised theirs, arguing that senior housing and active adult assets offer better returns than medical offices.16 One bullish argument held that the stock trades near 9x FFO, well below its historical multiple.16 A trailing P/E of about 9 is also widely quoted.11 That P/E is inflated by the one-time sale gain and says little about ongoing earnings.

This split points to a broader issue for office-adjacent real estate. Medical office buildings have mostly avoided the problems hurting traditional office towers, and Chiron's outpatient occupancy has held near 95% to 96%.227 Chiron's management argues that stable, slow growth is not enough to earn a strong public-market valuation. Its answer is to take on operating risk: under the SHOP model, the landlord shares in the property's operating results and takes on more of the operating risk than a net lease landlord does.15

The verdict: a real transformation, not yet proven

The claim that the market undervalues Chiron has some merit, but the market's caution is reasonable. Chiron has done what it said it would do. It sold assets at a 7.3% cap rate, reduced leverage below 40%, brought in a committed investor whose capital converts at a premium, and closed its first senior housing deals.2723 The company's chief investment officer also bought shares in August at $37.21.6

On the other side, the stock trades well below the $43 conversion price. Core FFO is falling, same-store growth has slowed, borrowing costs are rising and the dividend has been cut.1121 Investors are being asked to give up predictable income now for returns from operating properties later.

In practice, the stock is now a bet on execution. The next checkpoints are the closing of the North Bethesda deal, how quickly the new communities fill up and how much more legacy outpatient property is sold. The next earnings report is expected around November 3.11 A discount will probably stay in place until senior housing NOI starts to offset the dilution in reported results.